GlassScriptPhysician profile
Eduardo E Cantu
NPI 1326190794
$2,776.88
in general payments reported to CMS, 2019-2025
23 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $690 · 2023: $299 · 2024: $709 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $903.53 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $307.66 | 2021-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $272.48 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.49 | 2021-2022 | |
| Lilly USA, LLC | $161.76 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Tactile Systems Technology INC | $137.56 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.08 | 2021-2025 | Jardiance, Ofev |
| Genentech USA, INC. | $113.81 | 2021 | |
| Idorsia Pharmaceuticals US INC | $98.90 | 2022 | |
| Smith+Nephew, INC. | $69.01 | 2024 | |
| United Therapeutics Corporation | $59.80 | 2025 | Steen Solution |
| Mylan Specialty L.P. | $45.48 | 2021-2022 | |
| Dexcom, INC. | $41.75 | 2024 | Dexcom G6 Transmitter |
| Nevro Corp. | $35.21 | 2022 | |
| Exact Sciences Corporation | $33.07 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.35 | 2023 | Repatha, Otezla |
| Abbott Laboratories | $18.65 | 2023 | Confirm Rx |
| Pfizer INC. | $18.32 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.86 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.39 | 2023 | Nuzyra |
| Amarin Pharma, INC. | $13.74 | 2021 | |
| Esperion Therapeutics, INC. | $13.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Cantu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.